These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8826903)

  • 41. New families with von Willebrand disease type 2M (Vicenza).
    Zieger B; Budde U; Jessat U; Zimmermann R; Simon M; Kätzel R; Sutor AH
    Thromb Res; 1997 Jul; 87(1):57-64. PubMed ID: 9253800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtype.
    Mazurier C; Mannucci PM; Parquet-Gernez A; Goudemand M; Meyer D
    Am J Hematol; 1986 Jul; 22(3):301-11. PubMed ID: 3087159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Presentation and diagnosis of patients with type 3 von Willebrand disease in resources-limited laboratory.
    Abdulsalam AH; Ghiath Y; Alrahal N
    Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):211-214. PubMed ID: 31796201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
    Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
    Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
    de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
    Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
    Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
    Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of von Willebrand factor in factor VIII concentrates.
    Fricke WA; Yu MY
    Am J Hematol; 1989 May; 31(1):41-5. PubMed ID: 2495715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of slightly reduced von Willebrand factor activity.
    Bykowska K; Ceglarek B
    Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.
    Mannucci PM; Lombardi R; Bader R; Horellou MH; Finazzi G; Besana C; Conard J; Samama M
    Blood; 1984 Sep; 64(3):614-21. PubMed ID: 6432075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A.
    Stokol T; Trepanier L; Parry BW; Finnin BC
    Res Vet Sci; 1997; 63(1):23-7. PubMed ID: 9368952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
    Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
    Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
    Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
    Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.